{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T07:04:08Z","timestamp":1784963048286,"version":"3.55.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.cllc.2019.09.004","type":"journal-article","created":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T17:38:16Z","timestamp":1569519496000},"page":"247-254","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"title":["Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer"],"prefix":"10.1016","volume":"21","author":[{"given":"Hui","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyang","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaxin","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuxiang","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misako","family":"Nagasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang W.","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingsheng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai-Hong Ignatius","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2019.09.004_bib1","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.cell.2007.11.025","article-title":"Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer","volume":"131","author":"Rikova","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.cllc.2019.09.004_bib2","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.cllc.2019.09.004_bib4","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1200\/JCO.2017.73.1323","article-title":"Further advances in the management of anaplastic lymphoma kinase\u2013mutated non\u2013small-cell lung cancer","volume":"35","author":"Ou","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2019.09.004_bib5","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/nrclinonc.2017.127","article-title":"Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance","volume":"14","author":"Schram","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.cllc.2019.09.004_bib6","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/nrc3612","article-title":"Tyrosine kinase gene rearrangements in epithelial malignancies","volume":"13","author":"Shaw","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.cllc.2019.09.004_bib7","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/35077225","article-title":"Oncogenic kinase signalling","volume":"411","author":"Blume-Jensen","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.cllc.2019.09.004_bib8","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2019.09.004_bib9","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.cllc.2019.09.004_bib10","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41598-017-00520-1","article-title":"Circulating tumor DNA mutation profiling by targeted next generation sequencing provides guidance for personalized treatments in multiple cancer types","volume":"7","author":"Shu","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.cllc.2019.09.004_bib11","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.jtho.2018.05.027","article-title":"Receptor tyrosine kinase fusions and BRAF kinase fusions are rare but actionable resistance mechanisms to EGFR tyrosine kinase inhibitors","volume":"13","author":"Schrock","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2019.09.004_bib12","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1158\/2159-8290.CD-18-1022","article-title":"Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion","volume":"8","author":"Piotrowska","year":"2018","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.cllc.2019.09.004_bib13","article-title":"Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study.","author":"Papadimitrakopoulou","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2019.09.004_bib14","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.cllc.2018.07.008","article-title":"Cell-free DNA next-generation sequencing prediction of response and resistance to third-generation EGFR inhibitor","volume":"19","author":"Helman","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2019.09.004_bib15","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-17-2310","article-title":"Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients","volume":"24","author":"Yang","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2019.09.004_bib16","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","article-title":"Trimmomatic: a flexible trimmer for Illumina sequence data","volume":"30","author":"Bolger","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.cllc.2019.09.004_bib17","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1101\/gr.129684.111","article-title":"Varscan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing","volume":"22","author":"Koboldt","year":"2012","journal-title":"Genome Res"},{"key":"10.1016\/j.cllc.2019.09.004_bib18","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1093\/bioinformatics\/btu549","article-title":"FACTERA: a practical method for the discovery of genomic rearrangements at breakpoint resolution","volume":"30","author":"Newman","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.cllc.2019.09.004_bib19","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.1158\/1078-0432.CCR-19-0585","article-title":"Comprehensive genomic profiling identifies novel genetic predictors of response to anti-PD-(L)1 therapies in non-small-cell lung cancer","volume":"25","author":"Fang","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2019.09.004_bib20","article-title":"Clinicopathologic features of non-small-cell lung cancer harboring an NTRK gene fusion","volume":"2018","author":"Farago","year":"2018","journal-title":"JCO Precis Oncol"},{"issue":"suppl 8","key":"10.1016\/j.cllc.2019.09.004_bib21","article-title":"Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study","volume":"29","author":"Ramalingam","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2019.09.004_bib22","first-page":"2892","article-title":"EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)","volume":"5","author":"Midha","year":"2015","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.cllc.2019.09.004_bib23","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.1016\/j.cllc.2018.12.017","article-title":"Durable clinical response to crizotinib in IRF2BP2-NTRK1 non-small-cell lung cancer","volume":"20","author":"Wang","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2019.09.004_bib24","doi-asserted-by":"crossref","first-page":"S321","DOI":"10.1016\/j.jtho.2018.08.239","article-title":"Efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC)","volume":"13","author":"Doebele","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2019.09.004_bib25","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/2159-8290.CD-18-0484","article-title":"Repotrectinib (TPX-0005) is a next-generation ROS1\/TRK\/ALK inhibitor that potently inhibits ROS1\/TRK\/ALK solvent- front mutations","volume":"8","author":"Drilon","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.cllc.2019.09.004_bib26","doi-asserted-by":"crossref","first-page":"5832","DOI":"10.1158\/1078-0432.CCR-18-4049","article-title":"Analysis of cell-free DNA from 32,989 advanced cancers reveals novel co-occurring activating RET alterations and oncogenic signaling pathway aberrations","volume":"25","author":"Rich","year":"2019","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730419302621?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730419302621?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:10:20Z","timestamp":1761505820000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730419302621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S1525730419302621"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2019.09.004","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2019.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}